April 2018
NCI Standard Funding Opportunity Announcements | |||||||||||||||||||||
| Current and Recent Program Announcements | Current and Recent Requests for Applications | |||||||||||||||||||||
|
Current
and Recent NCI and Trans-NIH Initiatives |
Requests for Proposals
|
Standard Due Dates |
|||||||||||||||||||||
 NEW |
Adenoid Cystic Carcinoma Research Foundation
Projects supported by ACCRF fall into three broad categories:
| ||||||||||||||||||||
| Due Dates: | Continuous - Researchers wishing to submit a proposal should email ACCRF's Executive Director w/a 1 paragraph description of research project. If determined to be w/in research priorities, a request for a full proposal will be issued. |
| Amount & Project Period: | Not stated |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Grant Opportunities ACCRF Research Agenda |
| Ongoing | All Ranks | Federal | See BAA |
Army Research Office (ARO) Broad Agency Announcement (BAA)
for Basic and Applied Scientific Research
for Fiscal Years 2017 through 2022
The purpose of this BAA is to solicit research proposals in the
engineering, physical, life, and information sciences for
submission to the Army Research Office (ARO) for consideration
for possible funding. Whitepapers and proposals will be
evaluated only if they are for fundamental scientific study and
experimentation directed toward advancing the scientific state
of the art or increasing basic knowledge and understanding.
| Due Dates: | Open until Mar. 31, 2022 Proposers are to submit white papers prior to submission of a complete proposal. Based on assessment of white papers, feedback will be provided to encourage or discourage submission of full proposals. |
| Amount & Project Period: | No specific dollars have been reserved - 3 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research - (x6804) |
| Link: | Funding Opportunities - Open Broad Agency Announcements (BAA) |
| Open | All Ranks | Non-federal | Clinical Trials |
The Gateway for Cancer Research
Research Grants
Gateway focuses on transformational science via effective
clinical trials - when basic science translates into human
testing and clinical practice. | Due Dates: | Rolling requests for funding conducted in two stages: a Letter of Intent (LOI) and if invited, a full application. Applicants must submit via Gateway's Grant Management System |
| Amount & Project Period: | Funding is variable and duration is 1 to 3 years |
| Eligibility: | All Ranks |
| Contact: | Gateway Contacts are: Jerian Dixon-Evans, Research Grants Specialist Jerian.Dixon-Evans@gatewaycr.org (847) 342-7361 and Domarina Oshana, Ph.D., Director of Research and Grants Domarina.Oshana@gatewaycr.org (847) 342-7443 |
| Link: | Grant Application Process |
NEW
Pre-announcements
| To Be Announced | See Announcements | Federal | See Specific Program |
Congressionally Directed Medical Research Programs
Upcoming Funding Opportunities
Although funds have not been appropriated for FY18, CDMRP is providing
information in these pre-announcements to allow investigators
time to plan and develop ideas for submission to the anticipated
FY18 funding opportunities. Pre-Announcements have been issued
as follows. Click on the link for additional information.1. Department of Defense Peer Reviewed Medical Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
2. Department of Defense Ovarian Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
3. Department of Defense Bone Marrow Failure Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
4. Department of Defense Breast Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2018
5. Department of Defense Lung Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
6. Department of Defense Peer Reviewed Cancer Research Program Funding Opportunities for Fiscal Year 2018 (FY18)
| March 19 | Junior Faculty | Non-federal | Career Development |
Prostate Cancer Foundation
2018 Young Investigator Awards
Research proposals submitted in consideration for this award
should, if successful, provide high impact to the field.
"Small-step" or incremental proposals are usually
non-competitive. Highly innovative basic science programs will
be carefully considered, but priority will be given to "bench to
bedside" translational research proposals w/potential to deliver
near term benefit to patients. Successful applicants should be
working in a research environment capable of supporting
transformational prostate cancer research. Access to and
interaction with a clinical environment and translational
prostate cancer physician-scientists is highly desired.| Due Dates: | Mar. 15 (OSR) Ι Mar. 19 (Sponsor) |
| Amount & Project Period: | $225,000 - 3 years |
| Eligibility: | S/be w/in 6 years
following completion of a professional degree; Must hold title of Postdoc, Instructor, Research Associate, Asst. Professor or equiv.; Must be under direct supervision of a mentor(s) and at least 1 mentor must reside at applicant's institution; Have received no more than $200,000 in current direct research funding from all sources including institutional funds during the 3-year term of this award |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA |
| March 19 | Graduate Students/Postdocs | Non-federal | Career Development/Travel Support |
Lymphatic Education & Research Network (LE&RN)
LE&RN
Travel Awards 20th International Vascular Biology Meeting in
Helsinki
Travel awards are being offered to defray
registration and travel costs associated with attendance at the
2018 meeting.
| Due Dates: | Mar. 19 (Sponsor) |
| Amount & Project Period: | Support to defray registration and travel costs associated with attending the 20th International Vascular Biology Meeting in Helsinki, Finland (June 3-7, 2018). |
| Eligibility: | Must be actively
enrolled in a doctoral program, residency or accredited
program of postdoctoral graduate education in the biomedical sciences.
Other trainees will be considered at the discretion of LE&RN and the
Review committee; Must be a current LE&RN supporting member in good standing through December 31, 2018 or later (become a Supporting Member here) |
| Contact: | Please contact LE&RN at lern@lymphaticnetwork.org. |
| Links: |
LE&RN Travel Awards 20th International Vascular Biology Meeting in Helsinki, Finland (June 3-7, 2018) |
NEW
| March 19 | All Ranks | Non-federal | Brain Tumors |
The Brain Tumour Charity
Expanding Theories/Pilot Projects
This initiative funds pilot projects to: Explore theories with
the potential to open new avenues of investigation and generate
data to increase confidence in the concept and support a further
future grant application. All applications must focus on
research priorities highlighted in in the BTC Research Strategy
A Cure Can't Wait. | Due Dates: | Mar. 15 (OSR) Ι Mar. 19, 5:00pm GMT (Sponsor) |
| Amount & Project Period: | £60,000/yr. - 2 years Award will be made in Pounds Sterling and will be cash limited at point of award. It will be Lead Institution's responsibility to make conversions into other currencies. The Charity is not responsible for any fluctuations in exchange rate over the course of the program. Lead Institution is advised to establish a corporate exchange rate agreement if conversion to other currencies is required. |
| Eligibility: | All Ranks - Open to international researchers,
but applications including a UK collaborator will be looked on
favorably; PI must hold an academic or research position |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Funding Opportunities Guidance Notes proposalCENTRAL (Submission Site) |
NEW
Restricted Submission
| March 21 (Pre-app.) | All Moffitt Faculty Ranks | Non-federal | Translational |
V Foundation for Cancer Research
Translational Research Projects
(Restricted - 2 applications will be selected)
This opportunity for translational research projects brings
together pre-clinical and clinical investigators. Translational
projects should move a novel strategy from the laboratory into a
human clinical trial or use specimens from a clinical trial to
develop biomarkers or mechanisms. Research projects that focus
on the biological basis of cancer are also encouraged. Research
on the biological basis of cancer disparities experienced by
patients from minority ethnic or racial populations in areas
related to causes, aggressiveness, treatment or relapse is also
encouraged.
| Due Dates: | March 21 (Pre-applications include a one-page
letter of introduction and two-page outline and are submitted
electronically in a pdf file to
Maureen Ahearn for REX
review and selection of final applicants by April 16th. ) Full Applications Due: May 28 (OSR) May 30 (Sponsor). |
| Amount & Project Period: | $600,000 - 3 years |
| Eligibility: | PI must: Be tenure-track faculty; (Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for Principal Investigator nomination .) Must be either a U.S. or Canadian Citizen, or have a legal permit to work in the U.S. (either temporary or permanent). |
| Contact: | Maureen Ahearn (x8824) |
NEW
| March 22 | All Ranks | Non-federal | Patient Safety |
The Doctors Company Foundation
2018 Grant Cycle
The purpose of the Foundation is to support patient safety
education for healthcare professionals in training and in
practice, and patient safety research with clinically useful
applications. In this context, patient safety is defined as a
healthcare discipline that minimizes the incidence and impact of
adverse events by redesigning systems and processes using human
factors principles to reduce errors.
| Due Dates: | Mar. 20 (OSR) Ι Mar. 22 (Sponsor) |
| Amount & Project Period: | Up to $50,000/yr. - 1 to 3 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | The
Doctors Company Foundation Grant Application Process |
Eastern Cooperative Oncology Group (ECOG) &
American College of Radiology Imaging Network (ACRIN)
| March 23 | Postdocs | Non-federal | Clinical Career Development |
ECOG-ACRIN Cancer Research Group
Eastern Cooperative Oncology
Group (ECOG)
Paul Carbone, MD Fellowship Award
The purpose
of this award is to develop and promote excellence in clinical
trials leading to improvements in cancer care.
| Due Dates: | Mar. 21 (OSR) Ι Mar. 23 (Sponsor) |
| Amount & Project Period: | $25,000 - 1 year |
| Eligibility: | Must meet all
of the following criteria: Completed two years of a fellowship in oncology or hematology at an ECOG-ACRIN member institution before the award's effective date of July 1; Must be actively involved in a cancer clinical trial and planning to conduct related research activity in the upcoming year; Not yet appointed to a first full-time faculty position as of the award effective date |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Paul Carbone, MD Fellowship Award |
| Admin. Supplement | NIH |
NEW
| March 26 | See Below | Federal | Sex/gender Influences |
Administrative Supplement for Research on Sex/Gender Influences (Clinical Trial Optional)
The purpose of this FOA is to support research highlighting the impact of sex/gender influences in human health and illness, including basic, preclinical, clinical, translational, and behavioral studies. Proposed research must address at least one objective from Goals 1 through 3 of the NIH Strategic Plan for Women's Health Research.| Due Dates: | Mar. 22 (OSR) Ι Mar. 26 (Sponsor) |
| Amount & Project Period: | $65,000 (Direct Costs) - 1 year |
| Eligibility: | See FOA for mechanisms eligible for supplement; Project/budget period must be w/in current project period of existing parent award; Parent grant must have at least 16 months of active grant support remaining from supplement application due date (e.g. 16 months from March 26, 2018). |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-658 |
NEW
| March 27 (LOI) | All Faculty Ranks | Non-federal | Ovarian |
The Honorable Tina Brozman Foundation for Ovarian Cancer Research Individual Investigator Awards
Tina's Wish awards annual grants to researchers proposing new ideas and concepts specifically for early detection or prevention of ovarian cancer.| Due Dates: | March 27 (Letter of Intent) Invited Applications: June 26 (OSR) Ι June 28 (Sponsor) |
| Amount & Project Period: | $100,000/yr. (Total) - 2 years |
| Eligibility: | Must hold position of Assistant Professor or higher (or equiv.) |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | RFA Ι LOI Info |
NEW
| March 30 (LOI) | Faculty Ranks | Non-federal | MDS |
Dresner Foundation Myelodysplastic
Syndromes (MDS) Fund
MDS Early Career and Established Investigator Research
Grants
The foundation will consider proposals for Early Career Awards
(ECA) and Established Investigator Awards (EIA). Research
proposed must be directly relevant to MDS or related conditions
and cannot already be fully funded.
| Due Dates: | March 30 (Letter of Intent) Invited Submissions: Jul. 18 (OSR) Ι Jul. 20 (Sponsor) |
| Amount & Project Period: | ECA: $250,000 - 2 years EIA: $500,000 - 2 years |
| Eligibility: | ECA:
Must be <5 years from completion of fellowship training
or postdoctoral program and/or have not previously been awarded an RO1
grant or its equiv. EIA: Must be >5 from completion of fellowship training or postdoctoral program, or to applicants who previously received an Early Career Award from the foundation or an RO1 grant or its equivalent. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | MDS Fund | MDS Application Guidelines |
NEW
| March 31 | All Ranks | Non-federal | Gynecologic |
Granulosa Cell Tumour Research
Foundation (GCTRF)
Pilot Research Funding
GCTRF strives to advance research in the treatment of granulosa cell tumor
of the ovary (GCT). The Foundation is open to receiving
proposals for funding of research that could lead to differences
in the clinic in the near term.
| Due Dates: | Mar. 28 (OSR) Ι Mar. 31, 5:00 PDT
(Sponsor) (Via email to grants@gctf.org.nz) |
| Amount & Project Period: | $20,000 - 1 year |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | GCTRF Ι Application for Research Funding |
| April 01 | All Faculty Ranks | Non-federal | Leukemia |
When Everyone Survives Leukemia Research Foundation
2018 Request for Proposals in Leukemia Research
This RFP solicits innovative research in leukemia and provides support for
laboratory, translational, or clinical research related to acute
leukemia.| Due Dates: | Mar. 28 (OSR) Ι Apr. 01 (Sponsor- Receipt Date) |
| Amount & Project Period: | $50,000 (Total Costs) - 1 year |
| Eligibility: | New and established investigators |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Guidelines |
| April 01 | All Faculty Ranks | Non-federal | Brain |
B*CURED
2018 Research Investigator Grant Program
Clinical doctors and research scientists whose primary focus is
brain cancer are invited to apply for a grant. Clinical and
translational projects with significant clinical promise will be
considered. Both adult and pediatric brain cancer projects will
be considered.| Due Dates: | Mar. 28 (OSR) Ι Apr. 01 (Sponsor) |
| Amount & Project Period: | $50,000 - 1 year |
| Eligibility: | All Faculty Ranks - must be: Undertaking clinical or translational research, w/intention of applying for R01 NIH funding or equivalent w/in 5 years, or Undertaking innovative research to bridge from bench to animal research or to acquire preclinical data from animal models; Formal involvement of a biostatistician is required for all clinical trial proposals, but not for pre-clinical or translational science proposals. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | 2018 Research Investigator Grant Ι FAQs |
Spring Cycle
| April 02 | See Below | Non-federal | See Below |
American Cancer Society - Spring 2018
| Due Dates: | Mar. 29 (OSR) Ι Apr. 02 (Sponsor) |
| Contact: | Office of Sponsored Research (x6804) |
| Primary Link: | proposalCentral |
Clinician Scientist Development Grant (CSDG)
This grant fosters development of clinicians to clinician scientists. Clinician scientists are investigators licensed to provide patient care and trained to conduct research. They pursue research questions across the cancer research continuum of relevance to improving health.| Amount & Project Period: | $135,000/yr. (Direct Costs) - 3 to 5 years |
| Eligibility: | Must be full-time and w/in first 6 years of
initial faculty appointment. Must be U.S. citizen or permanent resident of U.S. (See Eligibility, section 21 of the Grant Policies and Instructions for more information). |
| Links: | Overview Ι Grant Policies and Instructions |
Postdoctoral Fellowships
Supports training of researchers who have received a doctoral degree to provide initial funding leading to an independent career in cancer research (including basic, preclinical, clinical, cancer control, psychosocial, behavioral, epidemiology, health services and health policy research).| Amount & Project Period: | Stipends of $48,000, $50,000, and $52,000 per year, plus a $4,000 per year fellowship allowance - 3 years |
| Eligibility: | Must be U.S. citizen or permanent resident of U.S. |
| Links: | Overview Ι Policies and Instructions |
Mentored Research Scholar Grant
NOTE: This mechanism is being phased out. Only resubmissions will be reviewed in 2018. Provides support for mentored research and training to full-time junior faculty, typically within the initial four years of their first independent appointment. The goal is for these beginning investigators to become independent researchers as either clinician scientists or cancer control and prevention researchers.| Amount & Project Period: | $$135,000/yr. (Direct Costs) -5 years |
| Eligibility: | Junior faculty w/in first 4 years of first independent appointment. (See Eligibility, section 21 of the Grant Policies and Instructions for more information). |
| Links: | Overview Ι Policies and Instructions |
Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families
This RFA is limited to applications that focus on palliative care research projects for seriously ill cancer patients and their families in three specific areas:1. Exploring the relationship of pain and other distressing symptoms on quality and quantity of life, independence, function, and disability and developing interventions directed at their treatment in patients with advanced and chronic illnesses;
2. Studying methods of improving communication between adults living with serious illness, their families and their health care providers;
3. Evaluating models and systems of care for patients living with advanced illness and their families.
| Amount & Project Period:/strong | $60,000/yr. (Direct Costs) - 1 to 2 years |
| Eligibility: | All Faculty Ranks - Must have Full-time faculty position |
| Links: |
Overview Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families Policies and Instructions. |
New Initiative
| April 02 (LOI) | See Below | Non-federal | See Below |
American Cancer Society
New Initiative: Mission Boost Grants (MBG)
The purpose is to support select current and past ACS
grantees specifically for translation of their research to human
testing. These grants are opportunities for ACS grantees to seek
additional, or "boost" resources for innovative,
high-risk/high-reward projects. MBGs offer 2 stages of funding:The Primary Boost requires development of outcome-specific, unequivocal milestones that reduce risks of studying a new drug, device, or procedure in patients. The topic of study may be the same that was previously funded by the ACS grant, but it doesn't have to be. Primary MBG studies can be preclinical or clinical in nature.
The Secondary Boost requires the investigator to have successfully completed the Primary Boost milestones and submitted them to the Extramural Council for permission to move forward with this grant. The investigator may apply for a Secondary Boost grant to receive support for an additional period for advancing the research to clinical testing in cancer patients. Secondary MBG studies must involve testing in cancer patients.
The focus of the Mission Boost Program To be considered for an MBG, research projects must focus on studies in cancer patients, such as:
Treatment - First Time in Humans (FTIH); clinical proof-of-concept (PoC); side effect
reduction;
Diagnostics/Prognostics/Medical Devices - Clinical validation in humans;
Prevention - Including initial incidence or recurrence in humans (biomarker based/biomarker testing)
| Due Dates: | Apr. 02 (Letter of Intent) Jul. 12 (OSR) Ι Jul. 16 (Sponsor) |
| Amount & Project Period: | The Primary Boost: $200,000
(Direct Costs) -2 years The Secondary Boost: $300,000 (Direct Costs) - 18 months |
| Eligibility: | Must have held or
currently hold one of these grants (or previous versions of
such awards): Research Scholarship Grant (RSG), Mentored Research
Scholar Grant (MRSG), Cancer Control Career Development Awards (CCCDA),
or Pilot and Exploratory Projects in Palliative Care (PEP) award for a
minimum of one year. Note: For current ACS grantees, recommendation
is to delay submission of letter of intent (LOI) until last year of
grant since part of the LOI review may include consideration of
discoveries made under ACS support. Currently independent, full-time faculty Who's Not Eligible: People who have had only grants for ACS Postdoctoral Fellows or ACS Professors, without also having one of the grant types listed above. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | New Initiative Ι proposalCENTRAL (Submission site) |
| April 02 | Postdocs | Non-federal | Immunology/Tumor Immunology |
Cancer Research Institute Irvington
Postdoctoral Fellowship
Program
The Institute seeks hypothesis-driven, mechanistic
studies in both immunology and tumor immunology. Application
must clearly state potential of proposed studies to directly
impact understanding of the immune system's role in cancer risk,
tumor initiation, progression, metastasis, host response to
tumors and/or the treatment of cancer.| Due Dates: | Mar. 29 (OSR) Ι Apr. 02 (Sponsor) Additional 2017 Due Date: Oct. 01 |
| Amount & Project Period: | 3 years Annual Stipend: $55,000, $57,000 & $59,000 Institutional Allowance: $1,500/yr. |
| Eligibility: | Must have
doctoral degree by award activation; Must have < 5 years' postdoc experience; Must have < 3 years' experience in sponsor lab at award activation |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | Program Description Ι Instructions |
| R43/R44 | NIH |
| April 05 | Small Business Concerns (SBCs) | Federal | SBIR |
PHS 2018-02 Omnibus Solicitation of the NIH for Small Business Innovation Research Grant Applications (Parent SBIR Clinical Trial Required)
This FOA invites eligible U.S. Small Business Concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications in response to identified topics (see PHS 2018-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed.| Due Dates: | Apr. 05 (Sponsor) Additional Due Dates: Standard Dates |
| Amount & Project Period: | Phase I: $150,000 - 6 months Phase II: $1,000,000 - 2 years See FOA for detailed information about research split between SBC and partnering research institution. |
| Eligibility: | Only United States small business concerns
(SBCs) are eligible. (See FOA, Section II). Primary employment of the PD/PI (for both Phase I and Phase II) must be w/SBC at time of award and during conduct of proposed project. For projects w/multiple PDs/PIs, at least one must meet primary employment requirement. See SBIR/STTR Application Guide for specific details on eligibility requirements. |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-573 (R43/R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, and Fast-Track) |
| Companion FOA: | PA-18-574 (Clinical Trial Not Allowed) (R43/R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, and Fast-Track) |
| R41/R42 | NIH |
| April 05 | Small Business Concerns (SBCs) | Federal | Small Business Technology Transfer (STTR) |
PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Clinical Trial Not Allowed)(Parent STTR)
This FOA invites eligible U.S. Small Business Concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications in response to identified topics (see PHS 2018-2 SBIR/STTR Program Descriptions and Research Topics for NIH.| Due Dates: | Apr. 05 (Sponsor) Additional Due Dates: Standard Dates |
| Amount & Project Period: | Phase I: $150,000 – 1 year Phase II: $1,000,000 – 2 years See FOA for detailed information about research split between SBC and partnering research institution. |
| Eligibility: | Only United States small business concerns
(SBCs) are eligible (See FOA, Section III). PD(s)/PI(s) may be employed w/SBC or the single, "partnering" non-profit research institution as long as s/he has a formal appointment with or commitment to the applicant SBC, characterized by an official relationship with the SBC. Each PD/PI must commit a minimum of 10% effort and have formal appointment with or commitment to applicant SBC, characterized by an official relationship between the SBC and that individual. Such a relationship does not necessarily involve a salary or other form of remuneration. |
| Contact:/strong | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-575 (R41/R42 Small Business Technology Transfer (STTR) Grant - Phase I, Phase II, and Fast-Track) |
| Companion FOA: | PA-18-576 (Clinical Trial Required) (R41/R42 Small Business Technology Transfer (STTR) Grant - Phase I, Phase II, and Fast-Track) |
| R43/R44 | NCI |
| April 05 | Small Business Concerns (SBCs) | Federal | Cancer Relevant Technologies |
Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (Clinical Trial Not Allowed)
This FOA invites SBIR grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. Proposed research projects are expected to focus on development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both development and commercialization of these technologies. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.| Due Dates: | April 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Phase I awards: $150,000 - normally not to
exceed 6 mos. Phase II awards: $1,000,000 - normally not to exceed 2 years |
| Eligibility: | Only U.S. small business concerns (SBCs) are
eligible to submit applications (See FOA for details). Primary employment of PD/PI must be w/SBC at the time of award and during conduct of proposed project. For projects with multiple PDs/PIs, at least one must meet primary employment requirement. Occasionally, deviations from this requirement may occur. |
| Contact:/strong | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-303 |
| April 06 (Required Registration) | All Ranks | Non-federal | HIV/AIDS |
amFAR, The Foundation for AIDS Research
Impact Grants: Gaining Insights from the Clinic
The goal is to generate practical, implementable information to
facilitate design and interpretation of broadly generalizable
HIV cure clinical research. Specific areas of interest are to:
(1) Identify pre-ATI predictors of post-treatment control (PTC)
or delay to rebound; and (2) Diversify the HIV cure clinical
study population.| Due Dates: | Must
Register by
April 06, by 12:00pm ET (REQUIRED) to provide preliminary
information and to receive portal username, password and other Letter of
Intent materials. Apr. 11, 3:00pm, ET (Letter of Intent) Invited Submissions: Early August 2018 |
| Amount & Project Period: | 1.1: Meta-analysis of data from completed
clinical trials (1 year; Total Costs: $100,000) 1.2: Addition of study arm to an existing clinical trial (4 years; Total Costs: $300,000) 1.3: Addition of reservoir and outcome (PTC or delay to rebound) analyses to an existing clinical trial (4 years; Total Costs: $100,000) 2.1: Addition of a recruitment and retention intervention to an existing clinical trial (4 years; Total Costs: $50,000) 2.2: Characterization of clinical case studies (1 year; Total Costs: $75,000) |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Impact Grants Detailed Information about Funding Opportunities RFP |
Updated Information
| April 08 | See Below | Non-federal | Career Development |
American Society for Radiation Oncology
ASTRO 2018 Funding
Opportunities
ASTRO funds research in radiation biology, cancer biology and
radiation physics. THE 2018 cycle is now open.| Due Dates: | Apr. 05 (OSR) Ι Apr. 08 (Sponsor) |
| Eligibility: | Must have < 5
years in a faculty appt.(no higher than Asst. Professor) at application;
Must be an ASTRO member in good standing; If applicant has received other career development awards (e.g. R01, K08, or similar funding level) s/he is not eligible; At least 50% effort must be devoted to the goals of this award. |
| Contact: | Office of Sponsored Research (x6804) |
| Primary Links: |
ASTRO Funding
Opportunities proposalCENTRAL (Guidelines & Submission) |
ASTRO-BCRF Career Development Award to End Breast Cancer
Research must be focused on understanding or treatment of breast cancer and include use or impact of radiation treatment.| Amount & Project Period: | $200,000 - 2 years (to be combined with matching funds or in kind contribution from applicant's institution.) |
| Link: | ASTRO-BRCF CDA |
ASTRO-PCF Career Development Award to End Prostate Cancer
Research must be focused on understanding or treatment of prostate cancer and include use or impact of radiation treatment.| Amount & Project Period: | $225,000 - 3 years (to be combined with matching funds or in kind contribution from applicant's institution.) |
| Link: | ASTRO-PCF CDA Award |
| F- Series | NIH |
| April 08 | See specific FOA | Federal | Career Development |
Ruth L. Kirschstein National Research Service Awards (NRSA) Fellowship Funding Opportunities
Cycle 1 due date for the National Research Service awards is approaching. Below is a listing of the available opportunities. Please see each funding opportunity announcement for details regarding eligibility. With exception of Senior Fellowship awards, budgets are composed of stipends, tuition and fees, and institutional allowance, in accordance with Ruth L. Kirschstein National Research Service Award (NRSA) guidelines| PA-18-672 | Individual Senior Fellowship (Parent F33) |
| PA-18-670 | Individual Postdoctoral Fellowship (Parent F32) |
| PA-18-671 | Individual Predoctoral Fellowship Award |
| PA-18-666 | Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31) |
| April 09 | All Faculty Ranks | Non-federal | Lung |
CHEST Foundation
2018 Grant Cycle
Projects supported by the CHEST Foundation lead to breakthroughs
in treatment of chest diseases and patient care. Higher-level
translational research project is preferred (T1-T5; for
definitions, please see:
https://ctsi.mcw.edu/images/CTSI
Translational-Continuum.pdf); basic (cellular or animal)
research projects will not be considered.
| Due Dates: | Apr. 07 (OSR) Ι Apr. 09 (Sponsor- Receipt date) |
| Eligibility: | CHEST membership
required at application; Licensed physicians; Physicians-in-training (residents or fellows), other health-care professionals, or clinical researchers w/relevant experience also be accepted; Special consideration is given to young investigators and applicants in early stages of their careers. |
| Contact: | Office of Sponsored Research (x6804) |
| Primary Link: | 2018 RFPs |
Research Grant in Women's Lung Health
Applications must address important and timely issues surrounding women's lung health, including but not limited to diseases such as COPD and lung cancer.| Amount & Project Period: | $10,000 (Total Costs) - 1 year |
| Link: | Women's Lung Health |
Research Grant in Lung Cancer
Applications must address research that leads to improved medical and/or surgical detection, treatment, and/or cure of lung cancer. Higher-level translational research project preferred (T1-T5; for definitions, please see: https://ctsi.mcw.edu/images/CTSI Translational Continuum.pdf); basic (cellular or animal) research projects will not be considered.| Amount & Project Period: | $60,000 - 2 years |
| Link: | Research Grant in Lung Cancer |
| UG3/UH3 | NCI |
| April 09 (LOI) | All Ranks | Federal | Cancer Therapy |
Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (Clinical Trial Optional)
This FOA encourages applications to address development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials. The scientific scope includes:1. Development and optimization of QI tools and/or methods for treatment planning, predicting or measuring response to therapy as open source tools that will translate into clinical trial decision support;
2. Validation of the optimized tools in clinical settings to demonstrate their value for decision support in ongoing single-site or multi-site clinical trials.
A phased approach that emphasizes each of these activities must be proposed. Investigators must apply for both the UG3 and UH3 phases together in the single application.
| Due Dates: | Apr. 09 (Letter of Intent, Not required, or
binding) May 07 (OSR) Ι May 09 (Sponsor) Additional 2018 Due Date: Sept.12th |
| Amount & Project Period: | UG Phase: Max: $300,000/yr.
(Direct Costs) - 2 years; UH Phase: Max: $500,000/yr. (Direct Costs) - 3 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-248 |
| Companion FOA: | PAR-18-249 (U01 Clinical Trial Optional) |
NEW
| April 09, 12:00pm ET | Established Investigators | Non-federal | Pediatric |
Pediatric SU2C
Catalyst®
Supported by a grant from Bristol-Myers Squibb
The Pediatric SU2C Catalyst will support preclinical research
and early phase clinical trials to provide foundational data
that will allow pediatric trials progress in parallel to adult
clinical trials. Applications are encouraged to include a
combination of therapies and/or devices for refractory pediatric
cancers, and collaborations involving multiple companies are
welcome. All applications must include inter-institutional
collaborations.
| Due Dates: | Apr. 05 (OSR) Ι Apr. 09 (Sponsor by 12:00pm (noon) ET) |
| Amount & Project Period: | $3M (Total) - 4 years |
| Eligibility: | Team Leader, Team
Co-Leader, and Team Principals must have doctoral or medical
degree, and be independent investigators;
Team Leader will be primary contact, and must be identified as having expertise in pre-clinical, clinical, or translational research; Team Co-Leader must have expertise in different area from Team Leader; If project requests funding for a clinical trial, then either Team Leader or Team Co-Leader must be Clinical Leader for Team; Teams must include a Project Manager and an Advocate. (See Program Guide) No citizenship or residency requirements. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Program Guide Spreadsheet Templates Application Application Submission Site SU2C Catalyst |
| R01 | NCI |
| April 11 | All Ranks | Federal | "Chemobrain" |
Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (Clinical Trial Optional)
This FOA encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as "chemobrain."| Due Dates: | Apr. 09 (OSR) Ι Apr. 11
(Sponsor) Additional Due Dates: Oct. 10, 2018 and Apr. 11, 2019 |
| Amount & Project Period: | Budgets not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-605 |
| Companion FOA: | PAR-18-606 (R21) |
| U01 | NIH |
| April 11 | All Ranks | Federal | NIH Collaborative Research |
Opportunities for Collaborative Research at the NIH Clinical Center (Clinical Trial Optional)
This FOA supports collaborative translational research projects to enhance translation of basic biological discoveries into clinical applications that improve health. Specifically it seeks to broaden and strengthen translational research collaborations between basic and clinical researchers within and outside of NIH by providing support for extramural investigators to take advantage of unique research opportunities available at the NIH Clinical Center by conducting research projects in collaboration with NIH intramural investigators. See NCI specific area of interest in FOA.| Due Dates: | Apr. 09 (OSR) Ι Apr. 11 (Sponsor) |
| Amount & Project Period: | Max. $500,000/yr. (Direct Costs (total for extramural grantee, Clinical Center and Intramural investigator)) - 4 years |
| Eligibility: | All Ranks - Application requires
full collaboration of extramural PD/PI from applicant institution and
NIH intramural investigator. Multiple PD/PI (MPI) model is strongly encouraged but not required. For applicants opting to not use MPI model, NIH intramural investigator can hold any role other than PD/PI role. |
| Contact: | Office of Sponsored Research (x6804 |
| FOA Link: | PAR-18-646 |
| R01 | NCI |
| April 11 | All Ranks | Federal | Affective Processes |
Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (Clinical Trial Optional)
The purpose is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum.| Due Dates: | Full Applications: Apr. 09 (OSR) Apr. 11
(Sponsor) Note: Due date for optional LOI has passed Additional Due Dates: Oct. 10; and Apr. 11, & Oct. 11, 2019 |
| Amount & Project Period: | Application budgets not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-681 |
| R13 | NIH |
| April 12 | All Ranks | Federal | Conference/Meeting Support |
NIH Support for Conferences and Scientific Meetings (Parent FOA - Clinical Trial Not Allowed)
The purpose is to support high quality conferences relevant to the public health and to the scientific mission of the participating Institutes and Centers.| Due Dates: | Apr. 10 (OSR) Ι Apr. 12 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | The appropriate NIH Conference Grant Contact should be consulted for guidance regarding any IC-specific budget limitations or project duration requirements. Most ICs will accept applications for up to 5 years if a series of annual or biannual conferences are proposed by a permanently sponsoring organization. Support for conferences held on a less frequent schedule must be applied for individually. |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-648 |
NEW
| April 12 | All Ranks | Non-federal | Medical Marijuana |
Coalition for Medical Marijuana Research and Education
Funding Opportunity 2018-2019
Pilot Funding for Research and Education Projects
The State of Florida's Medical Marijuana Research and Education (MMRE)
Program invites proposals for funding of research and education
projects. General areas of interest include: 1. Projects aimed at developing a comprehensive evidence base on the short- and long-term health effects of marijuana for medical use, addressing the key gaps in the evidence base.
2. Educational projects to increase knowledge and understanding of current evidence on the short- and long-term health effects of marijuana use among health care professionals, policy makers, growers, marijuana dispensaries/pharms, public, patients and caretakers.
See Guidelines for additional detail on the areas of interest.
| Due Dates: | Apr. 10 (OSR) Ι Apr. 12 (Sponsor) Note that the due date has passed for optional letter of intent) |
| Amount & Project Period: | $200,000 (Direct Costs) - 1 year |
| Eligibility: | For Research topics,
applicant must hold academic position at a university or research
institution in Florida; For education topics, applicant should hold either academic position or position of authority requisite with proposed work such as non-profit program director or hospital management at a university, research institution, non-profit, hospital or other organization in Florida; An investigator may submit only one proposal as PI, but may be listed as co-investigator or collaborator on additional applications. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
MMRE Active Research MMRE Funding Opportunities Guidelines 2018-2019 MMRE Application Form 2018-2019 MMRE Budget Template |
| April 15 | All Ranks | Non-federal | Bridge Funding |
Rivkin Center for Ovarian Cancer
Bridge Funding
Bridge Funding allows researchers to produce data needed to substantiate a
proposal resubmission to federal funding agencies. Interim
funding is provided to researchers who have submitted an R01 or
R21 proposal to the NIH or an original proposal to the
Department of Defense (DoD) pertaining to ovarian cancer, have
not received but were close to, a fundable score.
Investigator-initiated projects in all areas of ovarian cancer
research are eligible. Special consideration will be given to
research that has clinical applicability. .| Due Dates: | Mar. 28 (OSR) Ι Apr. 15 (Sponsor) Additional Due Date: Oct. 15 |
| Amount & Project Period: | $30,000 - (Must have a duration of at least 6 months prior to resubmission to a federal funding agency) |
| Eligibility: | All Ranks Unfunded first submission NIH R01, R21, K08, K23, and K99 proposals (no A1 or A2 proposals) as well as original DoD proposals are eligible. NIH proposals must have scored in the 20th percentile or lower, and DoD proposals must have scored less than 2.5. Must have received agency score w/in past 9 months and must require at least 6 months of additional research prior to resubmission. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Award Guidelines Ι RFA |
Spring 2018 Cycle
| April 16 | Junior Faculty | Non-federal | Pilot Research |
Institutional Research Grant Program (ACS-IRG)
Pilot Awards-Spring 2018
The Spring cycle is open for pilot funding applications from
junior faculty to initiate cancer-related research projects that
can assist in successful submission of research proposals for
national grants.
| Due Dates: | Apr. 12 (OSR) OSR submits all Moffitt applications to the Intramurals Program by deadline. |
| Amount & Project Period: | $30,000 - 1 year |
| Eligibility: | Applicants w/in first six years of initial
faculty appointment; May be from Moffitt, USF or Ponce School of Medicine (PSM). Please review all criteria on pages 2-3 of Guidelines carefully to avoid being rejected without review. |
| Contact: | Maureen Ahearn (x8824) |
| Links: | Guidelines | Application |
| Admin. Supplement | NIH/ORWH |
| April 16 | See Below | Federal | Women's Health |
Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations – An ORWH FY18 Administrative Supplement (Clinical Trial Optional)
This FOA will support research focused on the effect of sex/gender influences at the intersection of a number of social determinants (e.g. race/ethnicity, socioeconomic status, education, health literacy and other social determinants in human health and illness). Proposed research must address an area specified within Objective 3.9 (Goal 3.0) of the NIH Strategic Plan for Research on Women's Health which states: "Examine health disparities among women stemming from differences in such factors as race and ethnicity, socioeconomic status, gender identity, and urban-rural living, as they influence health, health behaviors, and access to screening and therapeutic interventions."Projects must include a focus on one or more NIH-designated health disparities populations. Combination of one or more populations is also encouraged.
| Due Dates: | Apr. 12 (OSR) Ι Apr. 16 (Sponsor) |
| Amount & Project Period: | $200,000 (TOTAL) -1 year Project & budget period must be w/in currently approved project period for existing parent award. Parent grant must have at least 18 months of active grant support remaining from application deadline date. |
| Eligibility: | See
FOA for eligible funding mechanisms; One application per parent award allowed |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-676 |
NEW
| April 16 | NRG Oncology Members | Non-federal | Cancer Care Delivery |
NRG Oncology NCORP Cancer Care Delivery Research (CCDR)
Pilot Projects
CCDR is a multidisciplinary science seeking to improve clinical
outcomes and patient well-being by intervening on patient,
clinician, and organizational factors that influence care
delivery. A competitive pilot application would address/affirm
study implementation feasibility and portability to diverse
community-based practices (e.g., seamless study integration into
pre-existing clinical workflows). Consistent with core grant
objectives. CCDR funding priorities are listed in the
Summary.
| Due Dates: | Apr. 12 (OSR) Ι Apr. 16 (Sponsor) Submit by email to Karen Boparai (212)-717-2758 |
| Amount & Project Period: | $50,000 contingent upon NRG Oncology receipt of NOA from NCI Division of Cancer Prevention - 16 months (9/1/2018-12/31/2019) |
| Eligibility: | NRG Oncology Members
conducting research within an NCORP Community or Minority Site. Application must include an NRG rostered clinician as a study team member. PIs from Institutions allowing total award to fund research (and waiving in-directs) will be prioritized in review. |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Pilot Project Announcement Ι NRG Oncology |
| April 16 | Faculty Ranks | Non-federal | Diabetes and Cancer |
American Diabetes Association
2018 Core Research Program Grants
Call for Applications
Researchers are trying to discover more
about the complex relationships between diabetes and cancer.
There are risk factors shared between Diabetes and certain
cancers. Diabetes and cancer are considered to be inflammatory
diseases and involve inflammation at a cellular level.| Due Dates: | Apr. 12 (OSR) Ι Apr. 16 (Sponsor) |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Core Program |
Innovative Basic Science (IBS)
Supports basic research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of diabetes and its complications that holds significant promise for advancing prevention, cure or treatment of diabetes. Applications proposing high-risk projects with the potential for high-impact results are encouraged, as are studies that may not be sufficiently developed for traditional funding sources.| Amount & Project Period: | $345,000 (TOTAL) - 3 years |
| Eligibility: | All Faculty Ranks |
Innovative Clinical or Translational Science (ICTS)
Support for research with novel and innovative hypotheses, performed in human subjects, or research approaches to accelerate the transition of scientific discoveries into clinical application. Studies must directly involve human subjects, human samples and/or data, and offer considerable promise for advancing the cure, prevention or treatment of diabetes. Applications proposing high-risk projects with the potential for high impact results are encouraged, a are studies that may not be sufficiently developed for traditional funding sources.| Amount & Project Period: | $600,000 (TOTAL) - 3 years |
| Eligibility: | All Faculty Ranks |
Junior Faculty Development (JDF)
These awards support early investigators.| Amount & Project Period: | $552,000 (TOTAL) - 4 years |
| Eligibility: | Must be full-time
independent faculty w/< 10 years of research experience
since their terminal degree (Note tenure-track position not required); Cannot have previous or current NIH support (R00, R01, U01 or equivalent). May not hold concurrent awards of similar intent (NIH K awards, foundation or non-profit career development awards), however may have completed previous NIH K or other career development funding; Must dedicate at least 75% effort to research activities. |
Postdoctoral Fellowship (PDF)
Provides support for high quality training in disciplines and topics relevant to diabetes, in an environment conducive to beginning a career in diabetes research.| Amount & Project Period: | From $47,484-$55,581/yr. plus $5,000/yr. training and $5,000/yr. fringe benefit allowances - up to 3 years |
| Eligibility: | Researchers (PhD,
MD, PharmD, DO, DPM, or equiv.) w/confirmed postdoc position
by award start date; May not have more than 10 years research experience beyond conferral of doctoral degree; Must be authorized to work in U.S. or U.S. possessions |
Minority Postdoctoral Fellowship (PMF)
These fellowships are available to minority (African American or Black, Hispanic/Spanish/Latino, American Indian/Alaskan Native, and Native Hawaiian or Other Pacific Islander) postdoctoral researchers (MD, MD/PhD, PhD, DVM, or equiv.) who are underrepresented in biomedical research.| Amount & Project Period: | From $47,484-$55,581/yr. plus $5,000/yr. training and $5,000/yr. fringe benefit allowances - up to 3 years |
| Eligibility: | Researchers (PhD,
MD, PharmD, DO, DPM, or equiv.) w/confirmed postdoc position
by award start date; May not have more than 10 years research experience beyond conferral of doctoral degree; Must be authorized to work in U.S. or U.S. possessions |
NEW
| April 16 | All Ranks | Non-federal | Ovarian |
Ovarian Cancer Research Fund Alliance
(OCRFA)
Rosalind Franklin Prize for Excellence in Ovarian Cancer
Research
This is an annual prize awarded to an individual in recognition of his or
her outstanding contributions to basic science, translational,
or clinical research in ovarian cancer.
| Due Dates: | Apr. 16 (Sponsor) Submit application material as single PDF to grants@ocrfa.org |
| Amount & Project Period: | $10,000 prize (Prize Recipients will be presented with the award at the Ovarian Cancer National Conference, in Washington, DC, July 14, 2018) |
| Nomination Process: | The following are required: 1. A completed coversheet 2. Letter of nomination (1,500 words or less). In the letter, please describe the nominee's achievements in the field of ovarian cancer research. 3. CV for the nominee. |
| Eligibility: | Must hold
MD, PhD, or ScD degree, and an academic appointment at a non-profit
medical or research institution in the U.S.; Should have track record of high achievement in ovarian cancer research, demonstrated by significant contributions to care of women w/gynecologic cancer and to literature in the field; Should have obtained significant extramural research funding. |
| Contact: | Emily Hickey (Telephone: (212) 268-1002)) |
| Links: | Awards a & Prizes Ι OCRFA 2018 Franklin Prize Guidelines |
| April 23, 3:00pm ET | All Faculty Ranks | Non-federal | Prostate Cancer |
Prostate Cancer Foundation
2018 PCF Challenge Awards for Metastatic, Lethal Prostate
Cancer
The Request for Team Science Applications for PCF Challenge Awards is open.
Funding will be based on the level of innovation in applications
received. Research proposals in the following topic areas are
preferred:1. Immunotherapy for treatment of metastatic, lethal prostate cancer;
2. Targeted radionuclide therapy for advanced prostate cancer;
3. New systemic precision treatments for metastatic, lethal prostate cancer including those
targeting the currently "undruggable";
4. First-in-field research on new targets for systemic treatment of metastatic, lethal prostate
cancer;
5. Mechanisms of resistance to current and investigational drugs targeting the androgen
receptor and androgen axis, immune system, chemotherapy, and other targeted agents;
6. Correlative research around either clinical trials of novel agents or strategies or standard
of care;
7. Developing or validating biomarkers that guide therapy in patients or further
understanding of mechanisms by which therapies work;
8. Tumor microenvironment signaling related to cancer progression including the immune
component;
9. New bioinformatics technologies for analysis of genomic data and big data of clinical
outcomes.
| Due Dates: | Apr. 19 (OSR) Ι Apr. 23 (Sponsor, 3:00pm ET) |
| Amount & Project Period: | Up to $1M (Total) - 2 years |
| Eligibility: | Team should be
composed of at least 3 investigators capable of providing unique
scientific expertise; May be assembled from one institution, or several institutions; Must embed at least one young investigator as an integral contributor; Young investigator may hold title of Postdoc, Instructor, Research Assoc., Asst. Professor, or equiv., and be w/in 6 years of completing a professional degree (MD, DO, PhD, MD-PhD, DSc, ScD, DDM, DDS, DMD, MBBS, or equiv.) or subsequent mentored academic or clinical training program; S/he must have been awarded no more than $200,000 in direct research funding from all sources including institutional funds during the 2-year term of this award. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | RFA Ι SmartSimple (Submission site) Ι PCF for Researchers |
NEW
| April 23 | All Ranks | Non-federal | Patient Care |
Florida Blue Foundation
Improve Consumer Health
The purpose is to fund programs that support one or both of the
following funding areas:
1. Innovative programs that
propose evidence-based health solutions that serve underserved,
underinsured and low-income populations;2. Access to affordable, non-traditional health services (e.g., telehealth, "meet them where they live" and other solutions).
| Due Dates: | Apr. 19 (OSR) Ι Apr. 23 (Sponsor) Clarification Conference Calls: 1) March 19, 10:00 - 11:00 am 2) March 20, 10:00 - 11:00 am |
| Amount & Project Period: | Average yearly is $80,000 - $100,000 - 3 or 4
years Priority given to applicants including collaborations and partnerships with other nonprofit organizations in Florida |
| Eligibility: | Must be
based in Florida; Must have capacity, expertise, resources, knowledge in the field and time needed to carry out intent of project; Must have expertise in delivering educational and awareness programs on targeted topics to targeted populations described in this application; Must have a five-year or longer track record in one or both of the funding areas; Must have capability to reach target populations described in application |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Improve Consumer Health |
| R01 | NCI |
| April 30 (LOI) | All Ranks | Federal | Cancer Imaging |
Perception and Cognition Research to Inform Cancer Image Interpretation (Clinical Trial Optional)
The purpose of this FOA is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.| Due Dates: | Apr. 30 (Letter of Intent, not required or
binding) Applications Due: May 25 (OSR) Ι May 30 (Sponsor) Additional Due Dates: Sept. 26th and May 30, & Sept. 26, 2019 |
| Amount & Project Period: | Application budgets not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-640 |
| Companion FOA: | PAR-18-641, R21 |
| April 30 | All Ranks | Non-federal | Research Projects |
Elsa U. Pardee Foundation
Research Grants
The Foundation
funds research directed toward identifying new treatments or
cures for cancer, and particularly encourages applications
allowing establishment of capabilities of new cancer
researchers, or new cancer approaches by established cancer
researchers.| Due Dates: | Apr. 26 (OSR) Ι Apr. 30 (Sponsor) Additional Annual Due Dates: Aug. 31 and Jan. 31 |
| Amount & Project Period: | Funding amounts not specified - generally one year |
| Eligibility: | All Ranks - new cancer researchers or new approaches by established cancer researchers |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Grant Application Process |
| U01 (Also see Companion RFAs) | NCI |
NEW
| April 30 (LOI) | All Ranks | Federal | NCI-supported Technology |
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (Clinical Trial Optional)
The purpose is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects proposing to expand upon original research question(s) or otherwise accelerate progress for parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.| Due Dates: | Apr. 30 (Letter of Intent, not required, or
binding) Applications Due: May 25 (OSR) Ι May 29 (Sponsor) Additional 2018 Due Dates: Sept. 28 |
| Amount & Project Period: | Not to exceed $150,000/yr. (Direct Costs) - up to 2 years, but not to exceed remaining number of years on parent grant. If a no-cost extension is needed on parent grant, it must be in place before revision application is submitted. |
| Eligibility: | All Ranks - Revision applications from active NCI U01 awardees. |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA-CA-18-007 |
| Companion RFAs: |
RFA-CA-18-006, R01 Research Project Grant RFA-CA-18-008, P50 Research Project - Cooperative Agreements RFA-CA-18-009, P01 Program Project Grant RFA-CA-18-010, U54 Resource-Related Research Projects - Cooperative Agreements |
NEW| May 01 (LOI) | Junior Faculty | Federal | Career Development |
Air Force Office of Scientific Research
2019 Young Investigator Program (YIP)
FA9550-18-S-0002
This program intends support for young career scientists and
engineers who have received Ph.D. or equivalent degrees by 1
April 2012 or later and who show exceptional ability and promise
for conducting basic research. See "Research
Interests of the Air Force Office of Scientific Research" | Due Dates: | May 01 (Letter of Intent) Jul. 30 (OSR) Ι Aug. 01 (Sponsor) |
| Amount & Project Period: | $450,000 - 3 years |
| Eligibility: | Must be U.S.
citizen, national, or permanent resident; See Section C.3.a.
Primary Investigator Employment Requirements in announcement; Must have rec'd. doctorate no earlier than April 01, 2012; Must hold full-time permanent, career- competitive, or tenure-track position. |
| Contact:/strong | Office of Sponsored Research (x6804) |
| Link: | FA9550-18-S-0002 |
NEW
| May 01 | All Ranks | Non-federal | Breast/Education |
Florida Breast Cancer Foundation (FBCF)
Education Grants
FBCF seeks to fund resourceful and innovative educational
projects in four key areas:1. Breast cancer education;
2. Survivorship education;
3. Provide education on breast health to young women and men;
4. Late stage breast cancer education
Please note that funding is not available for screening, treatment programs, one-time events, conferences, symposiums, seminars, and participation as an exhibitor, presentation, or attendance at health fairs, conferences, symposiums, and seminars.
| Due Dates: | Apr. 27 (OSR) Ι May 01(Sponsor) Electronic & Hardcopy |
| Amount & Project Period: | Up to $5,000 for projects in a single county;
Up to $10,000 for projects provided in multiple counties focusing on education in one on one or small group settings Duration: 1 year |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Breast Cancer Education Download 2018 Education RFP |
NEW
| May 01 | All Ranks | Non-federal | Pediatric Cancers |
Pediatric Cancer Research Foundation (PCRF)
2018 Grant Cycle
The Foundation offers funding in three areas: Basic Science Grants, Translational Research Grants and Emerging Investigator Fellowship Grants. | Due Dates: | Apr. 26 (OSR) Ι May 01 (Sponsor) |
| Eligibility: | All Ranks (Please see Emerging Investigator Fellowship Grant for additional eligibility detail) |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
PCRF Grant Cycle proposalCENTRAL (Grant Procedure &Submission site) |
Basic Research Science Grant
These awards primarily fund basic science, translational and/or clinical state of the art pediatric cancer research initiatives.| Amount & Project Period: | Up to $250,000/yr. - Duration is project dependent |
Translational Research Grant
These awards primarily fund new research protocols and therapies that hold promise for improved outcomes and accelerates cures from the laboratory bench to the bedside of children and teens with high-risk cancers. This Grant will be given to a program that involves open, multi-institutional cancer clinical trials, or consortia, and implements new approaches to therapy.| Amount & Project Period: | Up to $100,000/ yr. – Duration is project dependent |
Emerging Investigator Fellowship Grant
This award is designed to support Post-Doctoral Fellowships and Clinical Investigator training for emerging pediatric cancer researchers to pursue exciting research ideas.| Amount & Project Period: | Up to $50,000/yr. Can be renewed annually |
| Eligibility: | Applicants must
have completed two years of a fellowship, or Not more than two years as a junior faculty instructor or assistant professor at start of award period. |
NEW
| May 01 | Faculty Ranks (See Below) | Non-federal | Hematology |
American Society of Hematology (ASH)
Bridge Grants
The purpose of Bridge
grants is to provide support for ASH members who have applied for an NIH R01 or equivalent
award but have been denied funding due to budget cutbacks. These
grants are intended to help sustain recipients' research.| Due Dates: | Apr. 27 (OSR) Ι May 01 (Sponsor) |
| Amount & Project Period: | $150,000 - 1 year |
| Eligibility: | Must have
submitted a hematology-related R01 or R01-equiv. application
in past 18 months that was scored but not funded; may include a
first-time submission (18 month timeframe begins on date of NIH study
section review); Must have $50,000 matching commitment from institution identifying use of commitment (Inadequate documentation of match may result in rejection of application prior to review); Must be an ASH member in good standing (membership may be pending at time of application but must be approved by award activation; Must hold a faculty appointment; Other research funding may not exceed $250,000 annually. |
| Contact: | Office of Sponsored Research (x6804) |
| Link: | Apply for the ASH Bridge Grant |
NEW
| May 01 (LOI) | Postdocs/Junior Faculty | Non-federal | Hematology/Career Development |
American Society of Hematology
ASH Scholar Awards
The purpose of the ASH Scholar Awards is to provide partial
support during the period between completion of training and
establishment of independent career. ASH supports
Basic/Translational research and Clinical/Translational
research to include patient-oriented and outcome-based
research.| Due Dates: | May 01 (Letter of Intent) Applications Due: Jul. 30 (OSR) Ι Aug. 01 (Sponsor) |
| Amount & Project Period: | Fellow Scholars : $100,000 - 2 to
3 years Junior Faculty Scholars: $150,000 - 2 to 3 years |
| Eligibility: | Must be ASH
member in good standing at submission of LOI and for
duration of award; Must be U.S. citizen or hold current/valid visa; Research must be conducted in U.S.; Please see Eligibility Requirements for specifics related to Fellow Scholars and Junior Faculty Scholars; |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
Scholar Award ASH Scholar Award Terms and Conditions |
| K18 | NIH |
NEW
| May 01 | Established Investigators | Federal | Career Development |
Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (Clinical Trial Required)
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-18-349).| Due Dates: | Apr. 27 (OSR) Ι May 01 (Sponsor) Additional Due Date: April 13, 201 |
| Amount & Project Period: | Up to $80,000/yr. for salary; $20,000/yr. research development costs; Duration: 1 year |
| Eligibility: |
Award is intended for well-established investigators
w/established records of independent, peer-reviewed Federal or private
research grant funding. Candidate must have a research or health-professional doctoral degree. Candidate must have a "full-time" appointment, and is required to commit at least 50% effort (i.e., a minimum of 6 person-months) to their program of career development. |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-692 |
| Companion FOA: | PAR-18-349 (K18 - No Independent Clinical Trials) - Next due date is March 6, 2019 |
| U01 | NCI |
| May 05 (LOI) | All Ranks | Federal | "Traceback" testing |
Traceback Testing: Increasing Identification and Genetic Counseling of Mutation Carriers through Family-based Outreach (Clinical Trial Optional)
The purpose is to support pilot research projects using a "Traceback" approach to genetic testing women with a personal or family history of ovarian cancer and reaching out to family members to identify unaffected individuals at increased risk for cancer in different clinical contexts and communities, including racially/ethnically diverse populations.| Due Dates: | May 05 (Letter of Intent, not required, or
binding) Applications Due: June 01 (OSR) Ι June 05 (Sponsor) Additional Dates: Standard dates |
| Amount & Project Period: | Application budgets not limited - 4 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-616 |
| R01 | NIH |
| May 06 (LOI) | All Ranks | Federal | Disparities |
Surgical Disparities Research (Clinical Trial Optional)
The purpose is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. (See FOA for NCI topics of interest, Part II Section 1).| Due Dates: | May 06 (Letter of Intent, not required or
binding) Applications Due: June 05 (OSR) Ι June 07 (Sponsor) Additional Due Date: June 7, 2019 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-288 |
| Companion FOA: | PAR-18-289 R21 Clinical Trial Optional |
| R01 | NCI |
| May 07 (LOI) | All Ranks | Federal | Liver |
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (Clinical Trial Not Allowed)
The purpose is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the U.S.| Due Dates: | May 07 (Optional Letter of Intent) Applications Due: June 01 (OSR) Ι June 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | Application budgets not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-677 |
| Companion FOA: | PA-18-678 R21 (Standard dates) |
| U01 | NIH |
| May 08 | All Ranks | Federal | Biomedical |
Bioengineering Research Partnerships (Clinical Trial Optional)
This FOA Invites applications to accelerate development and adoption of promising tools and technologies that can address important biomedical problems. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.| Due Dates: | May 04 (OSR) Ι May 08 (Sponsor) Additional Due Date: Sept. 13 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-208 |
| Companion FOAs: |
PAR-18-206 R01 (Clinical Trial Optional) PA-18-286 R21 (Clinical Trial Optional) Due Dates: Standard dates for companion FOAs |
| U01 | NIH |
| May 09 (LOI) | All Ranks | Federal | Aging and Cancer |
Partnership for Aging and Cancer Research (Clinical Trial Not Allowed)
This FOA is a joint effort between NCI and NIA (that arose from discussions led by The Samuel Waxman Cancer Research Foundation (SWCRF)) to promote research regarding mechanisms by which aging affects cancer onset, progression, metastasis, and/or therapeutic response. To maximize collaborative interactions for this program, NIH extramural scientists will collaborate with investigators in the NCI Center for Cancer Research (NCI CCR) and/or the NIA Intramural Research Programs (NIA IRP) to address key questions on the aging contribution to cancer.| Due Dates: | May 09 (Letter of Intent, not required or
binding) Applications Due: June 06 (OSR) Ι June 08 (Sponsor) |
| Amount & Project Period: | Not to exceed $75,000/yr. (Direct Costs) for extramural research component - 2 years |
| Eligibility: | All Ranks - An investigator from NCI Center for
Cancer Research must serve as co-investigator, and collaborators from
NIA and other divisions in NCI intramural research program are also
encouraged. Intramural collaborators should be tenured or tenure-track scientists and should have had previous contact with the PD(s)/PI(s) regarding the collaborative project proposed in the application. |
| Contact: | Office of Sponsored Research (x6804) |
| Additional Program Contact: | Samuel Waxman (212) 241-7995 |
| FOA Link: | PAR-18-552 |
| NCI Collaboration Links: |
NCI Intramural Program Directory of NCI Principal Investigators |
NEW
| May 14 | All Ranks | Federal | Big Data |
National Science Foundation (NSF)
Critical Techniques, Technologies and Methodologies for
Advancing Foundations and Applications of Big Data Sciences and
Engineering (BIGDATA)
The BIGDATA program seeks novel approaches leading towards
further development of the interdisciplinary field of data
science. The program also seeks innovative applications in
domain science, including social and behavioral sciences,
education, physical sciences, and engineering. The solicitation
invites two categories of proposals: 1. Foundations (BIGDATA: F): those developing or studying fundamental theories, techniques, methodologies, and technologies of broad applicability to big data problems, motivated by specific data challenges and requirements; and
2. Innovative Applications (BIGDATA: IA): those engaged in translational activities that employ new big data techniques, methodologies, and technologies to address and solve problems in specific application domains. Projects in this category must be collaborative, involving researchers from domain disciplines and one or more methodological disciplines, e.g., computer science, statistics, mathematics, simulation and modeling, etc.
| Due Dates: | May 10 (OSR) Ι May 14 (Sponsor) Note: BIGDATA program Webinar (about NSF 18-539) - March 20, 2018 - 1pm - Click here to register |
| Amount & Project Period: | Max. $500,000/yr. - 3 to 4 years |
| Eligibility: | All Ranks - Note: An individual may participate as PI, co-PI, Senior Personnel, consultant, or any other role in no more than one proposal, or related subaward, submitted in response to this solicitation. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Solicitation:
18-539 Program Page: Critical Techniques, Technologies and Methodologies for Advancing Foundations and Applications of Big Data Sciences and Engineering (BIGDATA) |
| R01 | NIH |
NCI is a participating Institute
| May 14 | All Ranks | Federal | Native American Health |
Intervention Research to Improve Native American Health (Clinical Trial Optional)
The purpose of this funding opportunity announcement (FOA) is to encourage research to improve Native American (NA) health. NCI is interested in applications focusing on both individual and community interventions relating to primary and secondary cancer prevention and treatment. NCI is also interested in applications related to communication, attitudes, and knowledge of cancer risk factors (such as tobacco exposure, energy imbalance, and alcohol use).| Due Dates: | Apr. 13 (Letter of Intent) Applications Due: May 10 (OSR) Ι May 14(Sponsor) |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | BBudgets are not limited - 5 years |
| FOA Link: | PAR-17-473 |
| Companion FOA: | PAR-17-464, R21 |
| R01 | NCI |
NEW
| May 14 (LOI) | All Ranks | Federal | Tobacco & Health Disparities |
U.S. Tobacco Control Policies to Reduce Health Disparities (Clinical Trial Optional)
The purpose of this FOA is to support observational or intervention research focused on reducing cancer health disparities in tobacco use in the United States. It is specifically intended to stimulate scientific inquiry focused on innovative tobacco control policies.| Due Dates: | May 13 (Letter of Intent, not required or
binding) June 11 (OSR) Ι June 13 (Sponsor) Additional Due Dates: Oct 11, 2018; June 13 & Oct. 11, 2019; and June 15, 2020 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-675 |
| Companion FOA: | PAR-18-674 R21 |
| NCI participates | NIH |
NEW
| May 22 | All Ranks | Federal | Data-People-Systems |
National Science Foundation (NSF) and
National Institutes of Health (NIH)
Smart and Connected Health (SCH) Connecting Data, People and
Systems
The purpose of this interagency program, supported by NSF and
NIH, is to develop next-generation multidisciplinary science
that encourages existing and new research communities to focus
on breakthrough ideas in a variety of areas of value to health,
such as networking, pervasive computing, advanced analytics,
sensor integration, privacy and security, modeling of
socio-behavioral and cognitive processes and system and process
modeling. Effective solutions must satisfy a multitude of
constraints arising from clinical/medical needs, barriers to
change, heterogeneity of data, semantic mismatch and limitations
of current cyberphysical systems and an aging population. Such
solutions demand multidisciplinary teams ready to address issues
ranging from fundamental science and engineering to medical and
public health practice.
| Due Dates: | May 18 (OSR) Ι May 22 (Sponsor) Additional Due Date: Dec. 11th |
| Amount & Project Period: | $300,000/yr. (Total) - up to 4 years |
| Eligibility: | All Ranks - Note: An investigator may participate as PI co-PI, Project Director (PD), Senior Personnel or Consultant in no more than 2 proposals submitted in response to this solicitation. |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | Smart and Connected Health Ι NSF 18-541 |
NEW
| May 25 | Postdocs/New Faculty | Non-federal | Career Development/Myelomas |
Multiple Myeloma Research Foundation (MMRF)
2018 Research Fellow Awards
The goal of this initiative is to help support young
investigators to begin their studies in the field of multiple
myeloma while advancing the understanding of myeloma disease
biology, treatment and drug resistance. | Due Dates: | May 23 (OSR) Ι May 25 (Sponsor) |
| Amount & Project Period: | $75,000 - 1 year |
| Eligibility: | Must hold a
Ph.D., M.D. or equiv. degree; Must be at post-doctorate, clinical fellow; OR Assistant professor level beginning studies in multiple myeloma field under supervision of a research mentor or sponsor; Mentor required for both Postdoc and faculty applicants |
| Contact: | Office of Sponsored Research (x6804) |
| Links: |
MMRF Research Grants Program Guidelines | proposalCENTRAL (Submissions) |
| R01 | NCI |
NEW
| May 30 (LOI) | All Ranks | Federal | Provocative Cancer Questions |
Research Answers to National Cancer Institute's (NCI) Provocative Questions (Clinical Trial Optional)
The purpose of these RFAs is to support research projects designed to solve specific problems and paradoxes in cancer research as identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.| Due Dates: | May 30 (Letter of Intent, not required or
binding) Applications Due: June 27 (OSR) Ι June 29 (Sponsor) Additional 2018 Due Date: Oct. 30 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| RFA Link: | RFA-CA-18-019 |
| Companion RFA: | RFA-CA-18-020 (R21) |
| Additional Note: | Four additional FOAs are planned for revision applications (formerly known as competing supplements) to add PQ-relevant research to specific eligible NIH and/or NCI-supported parent awards. Watch for RFA-CA-18-020, RFA-CA-18-022, RFA-CA-18-023, and RFA-CA-18-024 for R01, U01, P01, and P50 awards, respectively. |
NEW
| May 31 | All Ranks | Non-federal | Ovarian |
Louisa M. McGregor Ovarian Cancer
Foundation
2018 T.E.A.L.® Medical Research and Awareness
Program Beneficiary
This program offers funding in support of
ovarian cancer research studies that are most aligned with that
mission as determined by the T.E.A.L.® board of directors and
scientific advisory board. The mission is to promote public
awareness of and education about signs, symptoms, and risk
factors of ovarian cancer, provide support to survivors, and
raise funds for research in order to find a cure.| Due Dates: | May 29 (OSR) Ι May 31 (Sponsor) |
| Amount & Project Period: | Up to $50,000/yr. |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| Links: | T.E.A.L. ® Beneficiaries Ι Application |
| R01 | NCI |
NEW
| June 05 | All Ranks | Federal | Tumor Monitoring |
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (Clinical Trial Optional)
The purpose of this FOA is to support projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.| Due Dates: | June 1 (OSR) Ι June 05 (Sponsor) Additional Due Dates: Standard dates |
| Amount & Project Period: | MAX. $499,999/yr. (Direct Costs) - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PA-18-629 |
| R21 | NIH |
NEW
| June 07 | All Ranks | Federal | Health Disparities |
Exploratory/Developmental Surgical Disparities Research (Clinical Trial Optional)
The purpose is to encourage developmental and exploratory research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. The goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, while employing multi-level strategies at the institutional and systems level.| Due Dates: | June 05 (OSR) Ι June 07 (Sponsor) Additional Due Date: June 07, 2019 |
| Amount & Project Period: | $275,000 - 2 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-289 |
| Companion FOA: | PAR-18-288 Surgical Disparities Research (R01 Clinical Trial Optional) |
| R01 | NCI |
| June 11 (LOI) | All Ranks | Federal | Adducts/Adductomics |
Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (Clinical Trial Not Allowed)
This FOA encourages research focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. Priority is on projects focusing on adductomic approaches, i.e., address some aspects of the totality of adducts. Projects should explore basic aspects of adducts/adductomics that may have potential utility in cancer detection, cancer prevention, and/or assessing cancer risks.| Due Dates: | June 11 (Letter of Intent, not required or
binding) Applications Due: Jul. 09 (OSR) Ι Jul. 11(Sponsor) |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-704 |
| Companion FOAs: |
PAR-18-703, R21 PAR-15-307, U01 |
| R01 | NCI |
NEW
| June 13 | All Ranks | Federal | Smoking Cessation |
Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (Clinical Trial Optional)
This FOA is intended to stimulate research efforts aimed at the development of smoking cessation interventions that: 1) are targeted to socioeconomically disadvantaged populations, and 2) could be made scalable for broad population impact.| Due Dates: | June 11 (OSR) Ι June 13 (Sponsor) Additional Due Dates: Oct. 11 and June 13, 2019 |
| Amount & Project Period: | Application budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-251 |
| Companion FOA: | PAR-18-250 R21 |
| R01 | NCI |
| June 13 | All Ranks | Federal | Cancer Communication |
Innovative Approaches to Studying Cancer Communication in the New Media Environment (Clinical Trial Optional)
This FOA invites applications seeking to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life.| Due Dates: | June 11 (OSR) Ι June 13 (Sponsor) Additional Due Dates: Oct. 11 and June 13, 2019 |
| Amount & Project Period: | Application budgets not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-638 |
| Companion FOA: | PAR-18-639 R21 |
| R01 | NIH |
NEW
| June 17 (LOI) | All Ranks | Federal | Substance Abuse |
Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (Clinical Trial Optional)
As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose is to support development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.| Due Dates: | June 17 (Letter of Intent, not binding or
required) Applications Due: Jul. 13 (OSR) Ι Jul. 17 (Sponsor) Additional 2018 Due Date: Nov. 13 |
| Amount & Project Period: | Max. $500,000/yr. (Direct Costs) - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-222 |
| Companion FOA: | PAR-18-223 R34 (Planning Grant) |
| R01 | NIH |
| June 21 | All Ranks | Federal | Image-guided Drug Delivery |
Image-guided Drug Delivery (Clinical Trial Optional)
This FOA will support innovative research projects focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.| Due Dates: | June 19 (OSR) Ι June 21 (Sponsor) Additional 2018 Due Date: Nov. 22nd |
| Amount & Project Period: | Budgets are not limited - 5 years |
| Eligibility: | All Ranks |
| Contact: | Office of Sponsored Research (x6804) |
| FOA Link: | PAR-18-252 |
Funding Opportunity Calendar
OSR's Grant News
grants.gov
NCI Funding Opportunities
NIH Guide to Grants & Contracts
RaceTracks
Federal Opportunities
Moffitt-Sponsored (Intramural) Opportunities
Opportunities Focused on Thoracic Oncology
Proposal Submission Form
Grants.gov Instructions
PHS398 Instructions
NIH 2590 Instructions
News
NIH Research Matters
The Cancer Letter
NIH News & Events
Federal Register
Science 360 News
PubMed
National Cancer Institute
Clinical Research
Who To Call in Clinical Research
Clinical Research FAQs
Data Safety Monitoring Plan
Liberty IRB
USF IRB
MRISignals@moffitt.org
